Five different peptides (Pl: 84-95; P2: 152-166; P3: 52-63; P4: 7-23; P5: 110-123) homologous to relatively hydrophilic regions of human erythropoietin (huEpo) have been synthesized to identify biologically active domains of the hormone. All peptides were able to induce high titers of peptidespecific antibodies in rabbits. Antisera from rabbits induced by recombinant huEpo (rhuEpo) contained a relatively high amount of antibodies preferentially directed against three peptides (P2, P4, and P5), of which P4 comprised the amino-RYTHROPOIETIN (Epo) is a heavily glycosylated E hematopoietic growth factor with a molecular weight (MW) of 34-Kd that stimulates the proliferation and terminal differentiation of erythroid precursor cells.'32 Major target cells within the erythroid lineage are erythroid colony-forming unit (CFU-E) and erythroid burst-forming unit (BFU-E). Exposure to hypoxia results in enhanced production of Epo in the kidney, which is under the control of transcriptional and posttranslational regulation mechanism? Epo induces the synthesis of globin, heme complex, and ferritin receptor. These processes are primarily initiated and maintained by the interaction of Epo with a receptor molecule on the surface of Epo-responsive cells:
terminal region, P2 the carboxyl-terminus, and P5 an interior region previously described as the receptor-binding site. The same three peptides were able to induce rhuEpo-specific antibodies, whereas P1 and P3 lacked this activity. Only peptide-P24nduced antisera inhibited the biologic activity of rhuEpo in a cell proliferation assay, indicating that the carboxyl-terminal region of the molecule is essentially involved in the biologic function of rhuEpo.
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rhuEpo was eluted with a linear n-propanollphosphate gradient and subsequently applied onto a gelfiltration column that was run under isocratic conditions. The eluted peak (280 nm) consisted of pure rhuEpo, as was controlled by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and silver staining. Specific activity of purified rhuEpo was 120,000 Ulmg.
For selection of peptide regions suitable for the production of antisera against rhuEpo the amino acid sequence of rhuEpo was analyzed using the computer programs of the University of Wisconsin Genetics Computer Peptides were selected according to high hydrophilicity, surface probability, and antigenic index. The amino acid residue numbers and the amino acid sequences were the following: Pl(84-95): SSQPWEPLQLHV; P2 (152-166): KLKLYT-CDSRVLERYLLEAKEAE, and P5 (110-123): RALRAQKEAI-SPPD. All peptides were synthesized by fluorenyl-oxycarbonyl (Fmoc) solid-phase peptide synthesis using an ACT model 100 automated peptide synthesizer (Zinsser, Frankfurt, Germany). Peptides P1, P3, and P5 were derivatized by cystein with a free thiol moiety at the N-terminus. The cystein residue was used for coupling the peptides to a carrier protein. Peptides P2 and P4 were coupled through an internal cystein residue.
For the immunization of rabbits (breeding colony of Behringwerke AG, Marburg, Germany) conjugates of antigen and keyhole limpet hemocyanin ( K L H ) were used. Purified rhuEpo was coupled to KLH as described.i6 rhuEpo-derived synthetic peptides were coupled to KLH using the following method: 30 mg KLH was dissolved in 3 mL 0.05 mol/L Na,HPO,, pH 8.0, and 3 mg maleiimidobutyric acid succinimide ester in 0.4 mL dimethyl formamid (DMF) was added. The solution was stirred for 1 hour and the activated KLH was desalted by gel filtration on Sephadex
1204
FIB1 ET AL acid analysis (10% to 15% of total weight of the final complex). The conjugates were dissolved in phosphate-buffered saline (PBS) and mixed with complete Freund's adjuvant (CFA). Preimmune sera were taken before the first subcutaneous (sc) immunization of 0.4 mg antigen in CFA. Two weeks later, a second sc immunization of 0.8 mg antigen in the same adjuvant was performed, which was followed 14 days later by a 5-day intravenous (IV) immunization of 0.1 mg of the antigen with aerosil as adjuvant." Five days later the sera were collected. The same immunization protocol was used for the production of rhuEpo-specific antisera, using the hormone coupled to KLH, respectively.
Microtiter plates were coated with rhuEpo protein (20 pg/mL) or peptide Pl-P5 (20 pg/mL) in carbonate buffer (60 mmoVL Na,CO,, pH 9.9). Diluted samples of antisera (0.5% bovine serum albumin [BSA] in PBS) were incubated with the immobilized antigen for 2 hours at room temperature and then washed three times with 0.05% Tween 20 in PBS. The plates were then incubated with goat antirabbit Ig F(ab'), fragments coupled to alkaline phosphatase (Sigma, Munich, Germany) in 0.5% BSA-PBS. After another three washing steps with 0.05% Tween-PBS and one with 0.2 mol/L Tris-HC1, pH 9.5, the plates were developed by use of p-nitrophenylphosphate in 1 moVL Tris-HCI, pH 9.5, and bound antibodies were quantified by measuring the amount of p-nitrophenol at 405 nm.
Samples of purified rhuEpo were separated on Pharmacia 10% to 15% gradient gels using the Phast Gel separation system (Pharmacia). After separation the protein was transferred to nitrocellulose filters by a dry blotting procedure as follows. A dry filter was put on top of the gel without pretreatment and several layers of dry tissue wipes were surmounted. After 2 hours the gel was dry, and the transfer was 90% complete. After transfer, the filter was cut in slices, saturated with 0.5% BSA in PBS (0.5% BSA-PBS) for 30 minutes, and was incubated overnight with anti-rhuEpo or anti-rhuEpo-peptide specific antisera in 0.5% BSA-PBS. The filters were washed three times with 0.05% Tween 20 in PBS (0.05% Tween-PBS) and were further incubated with goat antirabbit Ig F(ab'), fragments coupled to alkaline phosphatase (Sigma). After washing with 0.05% Tween-PBS ( 3~) and with 0.2 m o m Tris-HC1, pH 9.5 ( l x ) , the blots were developed with 5-bromo-4-chloro indoxyl phosphate p-toluidine (Bachem, Bubendorf, Switzerland) and nitro-blue tetrazolium (Sigma) in 1 mol/L Tris-HC1, pH 9.5, for 20 minutes.
Five-microgram quantities of rhuEpo (whole molecule) were radioiodinated with iodine-125 using the two-phase chloramine-T method described by Tejedor and Ballesta.'' Nonincorporated iodine was removed by gel chromatography on Sephadex (Pharmacia). Specific radioactivities of 600 GBq/g were obtained, corresponding to a degree of substitution of about 0.3 iodine atoms per protein molecule.
The titers of the Epo fragment antibodies were assessed via the binding of radioiodinated Epo. Constant amounts (1.0 ng) of radioactive Epo were incubated with 100 pL of diluted antibody on various levels of dilution (working dilutions in assay buffer 1:1000, 1:2000, and 1:4000, respectively). All incubations were set up in triplicate. To get a measure of the specificity of the binding, another set of test tubes was prepared additionally containing 1.0 pg of unlabeled Epo. Antiserum no. 199, which is specific for the whole rhuEpo molecule, served as a positive control. Assay buffer was used as negative control. The binding reaction was allowed to proceed at +4"C for 18 hours. Bound and unbound tracer antigen were then separated one from another by the addition of 1 mL each of solid-phase antirabbit IgG from donkey (Amerlex-M donkey antirabbit; Amersham-Buchler, Braunschschweig, Germany) and incubation at +4"C for 10 minutes followed 5y centrifugation, two Direct binding assay.
Gel electrophoresis and immunoblotting.
Preparation of radiolabeled Epo.
Radioimmunologic binding assay.
washings with assay buffer, and automatic gamma counting of the sediments that contained the bound tracer antigen.
rhuEpo-specijic proliferation assay. rhuEpo-induced proliferation was performed in a modified assay system according to Krystal." Female NMRI mice were injected with phenylhydrazine hypochloride (PH; 48 mg/kg) on 2 consecutive days. The spleens were removed 48 hours after the last PH injection. Erythroid progenitors were enriched by Ficoll gradient (D = 1.077), and the interphase cells were collected and washed twice with 20 mL of PBS and suspended in Dulbecco's modified Eagle's medium (DMEM). Samples of an rhuEpo dilution (0.1 pmoVmL final concentration) were added to 3 x 105 cells/well in 96-well microculture plates (100 )LL assay volume). After 24 hours of incubation at 37°C in humidified atmosphere (5% CO,), 20 pL of DMEM containing 1 pCi of methyL3H-thymidine were added to each well. The cells were labeled for 3 hours, and 'H-thymidine incorporation was determined in a TRI-CARB 6660 Liquid Scintillation Counter (Inotech, Wohlen, Switzerland). For inhibition of biologic activity, rhuEpo was preincubated with dilutions of antisera or preimmune serum. To prove the specificity of the neutralizing activity, the sera were administered to the cultures after preadsorption to the specific peptide coupled to sepharose according to Axen et al.*" The coupling reaction was performed with 30 mg of peptide P2 and 10 g of BrCN-activated sepharose (Pharmacia-LKB). For preadsorption peptide PZSepharose (500 pL) was incubated for 30 minutes with 1 mL of antiserum 448. During that time the sepharose beads sedimented. To complete sedimentation the samples were centrifuged for 3 minutes at 1,000 rpm. The supernatant was removed repeatedly after incubation with different portions of peptide-P2-sepharose. We identified five major hydrophilic regions of the h u E p o m 0 1 e c u l e . '~~~~ The selected peptides display high hydrophilicity values, as well as high surface probability and antigenic index values (Fig 1) . Four of them, P1, P3, P4, and P5, also have a high probability of forming a-helical structures, and the carboxylterminal region P2 is predicted to contain P-sheet and turn structures.
RESULTS

Immunogenic
To identify rhuEpo-specific antigenic regions on the selected five peptides, several rabbit anti-rhuEpo antisera were examined for binding to the peptides. For this purpose, microtiter plates were coated with the single peptides, and individual antisera were tested in a direct binding assay. The results are shown in Fig 2. All sera tested contained antibody fractions recognizing each of t h e peptides. However, depending on the peptide, the titers of the peptide-specific fractions strongly diverged. The data show that regions of t h e h u E p o molecule covered by peptides P2, P4, or P5 provide highly immunogenic epitopes for antibody induction in rabbits (Fig 2D, F, and G) . Comparison through G) with that to rhuEpo ( Fig 2B) shows a difference Characterization of antisera induced by huEpo peptides. Partial peptide sequences of proteins per se are suitable as epitopes, which mimic the antigenic property of the natural protein to induce specific antibodies that can recognize the whole protein Therefore, rhuEpo-derived synthetic peptides P1, P2, P3, P4, and P5 were coupled to KLH and used for immunization of rabbits. Peptide-specific antibodies could be induced with all peptides in several individual animals, and antisera with high titers of antibodies were obtained (Table 1) . Antigen specificity was confirmed by blocking studies, using free peptides as inhibitors (data not shown). Antibodies against P1, P2, P3, P4, and P5 also detected native rhuEpo bound to microtiter plates (Table 1, lane 2; Fig 3) . Highest antibody response was induced by peptides P2, P4, and P5 (Fig 3B, D , and E), whereas rhuEpo-specific titers were low in anti-P1 and anti-P3 antisera (Fig 3A and C) . These data suggest that the structures of the native huEpo molecule covered by the peptides P2, P4, and P5 are exposed on the surface (Table  1; Fig 3) . In contrast, peptides P1 and P3 probably do not represent surface epitopes of rhuEpo. Immunoblot analysis confirmed that antisera against P2, P4, and P5 react specifically with denatured rhuEpo (Fig 4b, d , and e). Although P1 and P3 induced high peptide specific titers (see Table l ), these antisera did not react with huEpo in immunoblots (Fig 4a and c) .
RECEPTOR-BINDING SITE OF HUEPO AT C-TERMINUS
We further analyzed the capacity of the antisera to bind to native radiolabeled rhuEpo in solution using an immunoprecipitation method. Only anti-P2 and anti-P4 antisera contained relatively high antibody titers specific for the native rhuEpo molecule (Table 2) . Peptide-P3-and -P5-specific antisera contained only very low rhuEpo-specific antibody titers (915,918, Table 2 ), whereas the peptide-P1-specific antisera had only background levels of binding activity to rhuEpo. However, because anti-peptide-P5 antiserum 915 had been reactive in enzyme-linked immunosorbent assay (ELISA) and immunoblot experiments, we analyzed antibody fractions of this serum affinity purified of twofold to 100-fold. on P5 sepharose. In these antibody fractions antibodies specifically binding to native rhuEpo clearly could be identified (915a, Table 2 ). However, the binding capacity was very low.
The carboxyl-terminus of Epo i s essential for biologic function. Antibodies with specificity to distinct protein regions have been described to perturb protein function.zz*z3 Therefore, antibodies binding to rhuEpo were examined for inhibitory effects on the biologic activity of the native hormone in an in vitro proliferation assay." As shown in Fig  SA, anti-rhuEpo serum 348 was able to block the function of rhuEpo totally after preincubation with the hormone for 1 hour before stimulation of the tissue culture. Preimmune serum had no inhibitory effect on rhuEpo-induced cell proliferation. To identify functionally important regions of the rhuEpo molecule, antibodies specific for peptides P2, P4, and P5 were studied in the same way for their effects on rhuEpo-induced proliferation. As shown in Fig 5, only antibodies specific for the carboxyl-terminal peptide P2 (serum 448) were able to block the proliferation of erythroid precursor cells. Antibodies induced by peptide P4 (serum 926) and peptide P5 (serum 915) did not block the biologic activity of EPO (Fig 5A) . However, because the region (AA 99-129) that is partially covered by peptide P5 had been shown to be involved in biologic a~tivity,'~ we used P5-specific antibody fractions of serum 915 for neutralizing the biologic activity of rhuEpo in the proliferation assay. However, even this affinity-purified antibody fraction lacked neutralizing activity (data not shown). To prove that the inhibition of rhuEpo-induced cell proliferation by anti-P2 sera was specific, antiserum 448 was preadsorbed to peptide PZSepharose. As shown in Fig 5B, the neutralizing activity of serum 448 could be completely removed by a fivefold preadsorption of serum 448 to PZsepharose.
DISCUSSION
To further define the biologically active domain of rhuEpo, rabbit antibodies were raised against five major hydrophilic peptide regions of the molecule. Three of them, peptides P2, P4, and P5, were able to provoke the produc- 
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A --tion of anti-rhuEpo antibodies, suggesting that they comprised immunologically relevant structures. In contrast, antibodies against the peptides P1 and P3 were not crossreactive with rhuEpo. Sytkowski and Donahue used a similar immunologic approach to map the active site of r h~E p o . '~ Although they were able to raise antibodies against the carboxyl-terminal 20 residue peptide (residues 147-166), their antisera did not cross-react with highly purified huEpo. We show here that antibodies raised against synthetic peptide P2 comprising carboxyl-terminal residues 152-166 are able to recognize DILUTION lXlooOl Fig 2. Direct binding of rhuEpospecific antisera to rhuEpo and to selected peptides. rfruEpo-specific antisera from individual rabbits were tested for antigen specificities. Microtiter plates (96 wells) were coated overnight with 0.5% BSA (A), 20 pg/mL of rhuEpo (6) . or 20 pg/mL rhuEpo-derived peptides (Pl, P2, P3, P4, and E). Then the plates were saturated with BSA and incubated with various dilutions of rhuEpo-specific antisera. Bound antibody was detected using goat antirabbit F(ab'), fragment coupled to alkaline phosphatase and quantified by photometric determination of p-Nitrophenol at 405 nm. Values correspond to the average of double determinations.
the rhuEpo molecule in its native and biologically active as well as in its partially denatured form using radioimmunoprecipitation, ELISA, or immunoblotting, respectively.
We further demonstrate that the carboxyl-terminus is at least part of the biologically active site of the rhuEpo molecule. Antisera against the carboxyl-terminal peptide (P2) of rhuEpo were able to block the biologic activity of the hormone completely, whereas antibodies specific for regions other than the carboxyl-terminal sequences failed to do so. The inhibition of biologic activity could be a result of direct blocking of the receptor-binding site or of conforFor personal use only. on November 11, 2017 . by guest www.bloodjournal.org From 
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Binding of anti-rhuEpo and anti-rhuEpo peptide-specific antisera to the inducing antigens in a solid phase ELISA. Antibody titers were determined by titration of twofold dilutions of different antisera in microtiter plates (96 wells) coated with 20 kg/mL of homologous peptide or 20 pg/mL of rhuEpo. Bound antibody fractions were detected with goat antirabbit F(ab'), fragments coupled to alkaline phosphatase. The procedures and evaluations were performed as described in Fig 2. The values correspond to double determinations of the half maximal optical density at 405 nm.
mational changes through antibody binding to the hormone. However, because of the completeness of the inhibition, we would favor the first assumption. Antibodies raised against carboyl-terminal peptide 147-166 by Sytkowski and
wn PI -6 -A Donahue" did neither detect the native Epo molecule nor exhibit a neutralizing activity. However, Sytkowslq and Donahue proposed another region as a biologically active domain of rhuEpo, located between residues 99 and 129. In their study, antisera specific for two overlapping peptides from amino acid 99 to 118 and 111 to 129 could block biologic activity by about 75%. Antibodies against one of our peptides from the same region (residues 110 to 123, peptide P5) did not inhibit the biologic activity, although rhuEpo was recognized by these antibodies in ELISA and immunoblot experiments. However, when we tested the binding capacity of P5-specific antiserum 915 to native radiolabeled Epo, we realized that the antiserum was of low rhuEpo-specific antibody titer. Furthermore, antibodies of that serum, which were affinity purified with P5-sepharose, could not neutralize the biologic activity. This finding indicated that the peptide P5 had induced another set of antibody species than the peptides covering the same region of rhuEpo used by Sytkowski and D0nah~e.z~
The N-terminal region of huEpo, represented by peptide P4, carried a third relatively immunogenic structure of the peptides analyzed. In the native huEpo this region is Purified rhuEpo was separated on a 10% to 15% polyacrylamide gradient gel and plotted to nitrocellulose (NC). The NC filter was cut into strips and each strip was incubated with an individual rabbit antiserum, eg, anti-P1 (a), anti-PP (b), anti-P3 (c), anti-P4 (d), anti-P5 (e), anti-Epo (f), and rabbk preimmune serum (9) . The strips were then incubated with goat antirabbit F(ab'), fragments coupled to alkaline phosphatase and developed with phosphatase substrate (see Materials and Methods).
coupled to the carboxylterminal domain via disulfide bond.25' Using the immunoprecipitation method, a high amount of rhuEpo-binding activity was detected in P4-specific antisera that could only partially be competed by cold rhuEpo (Table 2) . Despite the high binding activity of this serum to native rhuEpo, no inhibition of biologic activity was observed in the huEpo-specific proliferation assay." This finding is in agreement with studies describing activity of anti-huEpo antibodies against the N-terminal region. None of these antisera or a monoclonal antibody specific for this region were able to block biologic a~tivity.~,~' Thus, the suggestion that this region is not involved in the receptorbinding domain of rhuEpo is confirmed by our data. 
